Deferred Tax Assets, Valuation Allowance of CNS Pharmaceuticals, Inc. from 31 Dec 2018 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
CNS Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2018 to 31 Dec 2024.
  • CNS Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $15,302,000, a 20% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

CNS Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $15,302,000 +$2,535,000 +20% 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q4 2023 $12,767,000 +$4,077,000 +47% 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q4 2022 $8,690,000 +$3,012,000 +53% 31 Dec 2022 10-K 01 Apr 2024 2023 FY
Q4 2021 $5,678,000 +$2,942,000 +108% 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q4 2020 $2,736,000 +$1,788,000 +189% 31 Dec 2020 10-K 03 Mar 2022 2021 FY
Q4 2019 $948,000 +$731,200 +337% 31 Dec 2019 10-K 12 Feb 2021 2020 FY
Q4 2018 $216,800 31 Dec 2018 10-K 12 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.